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Background: Leishmaniasis is a neglected tropical parasitic diseases affecting millions of people around the
globe. Quinazolines are a group of compounds with diverse pharmacological activities. Owing to their promising
antileishmanial activities, some 3-aryl-2-(substitutedstyryl)-4(3H)-quinazolinones were synthesized in good yields
(65.2% to 86.4%).
Results: The target compounds were synthesized by using cyclization, condensation, and hydrolysis reactions. The
structures of the synthesized compounds were determined using elemental microanalysis, infrared (IR), and proton
nuclear magnetic resonance (1H NMR). The in vitro antileishmanial activities of the synthesized compounds were
evaluated using Leishmania donovani strain. All the synthesized compounds displayed appreciable antileishmanial
activities (IC50 values, 0.0128 to 3.1085 μg/ml) as compared to the standard drug miltefosine (IC50 = 3.1911 μg/ml).
(E)-2-(4-chlorostyryl)-3-p-tolyl-4(3H)-quinazolinone (7) is the compound with the most promising antileishmanial
activities (IC50 = 0.0128 μg/ml) which is approximately 4 and 250 times more active than the standard drugs
amphotericin B deoxycholate (IC50 = 0.0460 μg/ml) and miltefosine (IC50 = 3.1911 μg/ml), respectively.
Conclusions: The results obtained from this investigation indicate that the synthesized and biologically evaluated
quinazoline compounds showed promising antileishmanial activities and are good scaffolds for the synthesis of
different antileishmanial agents.
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Leishmanisis is a neglected tropical disease resulting from
infection of macrophages by obligate intracellular para-
sites of the genus Leishmania [1-3]. It is a public health
problem in at least 88 countries with an estimated 350
million people at risk. The estimated global prevalence of
all forms of the disease is 12 million. Every year, 1.5 to 2
million new cases and 70,000 deaths occur due to cutane-
ous leishmaniasis (CL). In addition, 500,000 new cases
and 59,000 deaths from visceral leishmaniasis (VL) occur
annually [4]. The number of cases of leishmaniasis is
increasing globally due to Leishmania/HIV co-infection
[5,6], international travel, and migration of immigrants
and refugees from endemic regions [7,8].
The prophylactic treatment of leishmaniasis mainly
rely on vector and reservoir control [9-11]. Control of* Correspondence: yihenews@gmail.com
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in any medium, provided the original work is preservoir host and vector is difficult due to high coast,
operational difficulties, and frequent relapses in the
host [12]. Although considerable effort has been made
to produce vaccine candidates for the treatment of
leishmaniasis, there is no vaccine against any form of
human leishmaniasis yet [13-17].
Pentavalent antimonials (SbV) have been used for the
treatment of leishmania infections. Unfortunately, in many
parts of the world, the parasite has become resistant to
SbV [18]. Treatment failure to sodium stibogluconate
(SSG) is observed in Eastern Sudan [19] and in Tigray,
Northern Ethiopia [20]. Recent reports showed that pent-
amidine also developed resistance as well as difficulties in
treating patients with Leishmania/HIV co-infection [21].
Combination chemotherapy has improved prospects for
decreasing the emergence of drug resistance, increasing
activity, and reducing required doses and thereby toxic
side effects. In the previous study, WR 279,396 (a topical
formulation containing 15% paromomycin and 0.5%
gentamicin) was found to be safe and effective against CLn Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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paromomycin is the most cost-effective combination among
miltefosine-paromomycin and AmBisome-miltefosine [23].
So far, no combination chemotherapy has been used in
treatment programs, except paromomycin/SSG [24].
Tremendous quinazoline derivatives are synthesized in
the past two decades, using different synthetic pathways
[25-30], due to their diverse pharmacological activities
[31-36] including antileishmanial activities [37-40]. These
reports indicate that several quinazolines were synthesized
and tested for their antileishmanial activities, with the
aim of discovering alternative chemotherapeutic agents
for the development of new antileishmanials. Promising
antileishmanial activities were observed in some 4-
aminoquinazoline [37], indolo[2,1-b]quinazoline-6,12-dione
[38], and 2,3-disubstituted-4(3H)-quinazolinone derivatives
[39,40]. As part of the efforts to discover less toxic and
more effective drug analogues for the treatment of
leishmaniasis, we synthesized some 2,3-disubstituted-4




Anthranilic acid, acetic anhydride, aniline, p-toluidine,
o-toluidine, acetone, dimethylsulfoxide, anhydrous zinc
chloride, p-chlorobenzaldehyde, p-nitrobenzaldehyde, p-
hydroxybenzaldehyde, chloroform, absolute ethanol, resa-
zurin sodium salt, anhydrous petroleum ether, distilled
water, iodine, HCl, and KOH were used in the study.
Instruments and apparatuses
Melting points were determined in open capillaries using
electro-thermal 9100 melting point apparatus and were
uncorrected. Infrared (IR) spectra in nujol were recorded
with the SHIMADZU 8400SP FT-IR spectrophotometer
(Shimadzu Corporation, Nakagyo-ku, Kyoto, Japan), and
proton nuclear magnetic resonance (1H NMR) spectral
data were performed on Bruker Avance DMX400 FT-NMR
spectrometer (Bruker, Billerica, MA, USA) using tetra-
methyl silane (TMS) as internal standard. Silica gel TLC
plates of 0.25-mm thickness were used in the study.
Experimental animals and strains
Swiss albino male mice of weight 20 to 32 g and age 6 to 8
weeks (for acute toxicity test) were obtained from Biomed-
ical Laboratory, Department of Biology, Faculty of Science,
AAU. Leishmania donovani isolate used in this study was
obtained from Leishmania Diagnosis and Research Labora-
tory (LDRL) culture bank, School of Medicine, AAU.
Culture medium and conditions
RPMI-1640, 10% heat-inactivated fetal calf serum (HIFCS),
1% penicillin-streptomycin, and 1% L-glutamine weresupplied to make a complete culture medium. The L.
donovani isolate was grown first on Novy-MacNeal-
Nicolle (NNN) medium and then in tissue culture flasks
containing RPMI-1640 medium supplemented with 10%
HIFCS and 1% 100 IU penicillin/ml-100 μg/ml strepto-
mycin solution at 22°C for promastigotes.
Reference drugs
Miltefosine/hexadecylphosphocholine (AG Scientific, San
Diego, CA, USA) and amphotericin B deoxyhcholate
(Fungizone®, ER Squibb, Middlesex, UK) were employed
as reference drugs in the in vitro antileishmanial activity
testing of the synthesized compounds.
Preparation of stock and working solutions
Stock solutions of 10 mg/ml of the synthesized compounds
were prepared by dissolving each compound in DMSO.
Stock solutions were diluted using complete RPMI to
obtain aliquots of 10 μg/ml. Then, threefold serial dilution
with complete RPMI gave the final six working concentra-
tions (10, 3.33, 1.11, 0.37, 0.12, and 0.04 μg/ml) of each of
the synthesized compounds. Amphotericin B deoxycholate
and miltefosine, which were used as a positive control
for comparison of the antileishmanial activities of the test
compounds, were also made in threefold serial dilutions.
All the prepared drugs were stored at −20°C and retrieved
only during use [41].
In vitro antileishmanial activity
In a 96-well microtiter plate, 100 μl of each of the seven
threefold serial dilutions of synthesized compounds were
added in triplicate wells. Then, 100 μl of suspension of
parasites (3.0 × 106 promastigotes/ml of L. donovani) was
added in duplicate. Some of the wells contained only the
parasites which served as a positive control. The media
and DMSO alone acted as a negative control. The con-
tents of the plates were then maintained in humidified
atmosphere at 22°C under 5% CO2.
After 68 h of incubation, 10 μl of fluorochrome resa-
zurin solution (12.5 mg dissolved in 100 ml of distilled
water) was added into each well. The fluorescence intensity
was measured after a total incubation period of 72 h using
Victor3 Multilabel Counter (PerkinElmer, Waltham, MA,
USA), at an excitation wavelength of 530 nm and emission
wavelength of 590 nm [42]. The IC50 values were evaluated
from sigmoidal dose-response curves using GraphPad
Prism 5.0 software (GraphPad Software, Inc., San Diego,
CA, USA).
In vivo acute toxicity test
The oral acute toxicity of compound 7 that exhibited
promising antileishmanial activity was investigated using
male Swiss albino mice (approximately 20 g each) following
reported methods [43]. The experimental animals were
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and fasted overnight. Groups 1-5 received compound 7
suspended in a vehicle containing 1% gum acacia, in
doses of 10, 50, 100, 200, and 300 mg/kg, respectively.
The sixth group received vehicle containing 1% gum
acacia (served as a control group) at a maximum dose
of 1 ml/100 g of body weight by oral route. The mice
were observed closely for 24 h with special attention to
the first 4 h. Acute toxicity signs were checked in the
test mice.
Statistical analysis
The IC50 values for in vitro promastigotes assay of
synthesized compounds were evaluated from sigmoidal
dose-response curves using computer software Graph-
Pad Prism 5.0.
Results and discussion
Chemistry of the synthesized compounds
Synthesis of the target compounds involved the formation
of 2-5 and 10 as intermediates. It was accomplished using
nucleophilic reaction, nucleophilic with ring opening and
closing, condensation reaction, and hydrolysis reactions.
The target compounds are synthesized in a good yield,
which ranged from 65.2% to 86.4% (Table 1). All the
synthesized compounds were readily soluble in DMSO
and chloroform except compound 12 which is readily
soluble in acetone. Spectral data (IR and 1H NMR) of
the synthesized compounds were in full agreement with
the proposed structures.
Biological activity testing results
In vitro antileishmanial activity of the synthesized compounds
The antipromastigote activities of the synthesized com-
pounds and the standard antileishmanial drugs (ampho-
tericin B deoxycholate and miltefosine) were evaluated
using the clinical isolate of L. donovani strain. The IC50 of
the synthesized and reference drugs were evaluated from
fluorescence characteristic of AlamarBlue® (resazurin) (Trek
Diagnostic Systems, Inc., Cleveland, OH, USA) which is
soluble, stable in culture medium, non-toxic to cells, andTable 1 Physical constants and percent yield of the synthesiz







13 C24H22N2O3 386.45does not affect the secretary abilities of cells [44]. The test
works as a cell viability and proliferation indicator through
the conversion of resazurin to resorufin via reduction. The
amount of fluorescence produced is proportional to the
number of living cells [45,46].
The quinazolinone derivatives synthesized were shown to
have good antileishmanial activity which was in line with
the previous reports [37-40]. All the tested compounds
exhibited better antileishmanial activity than the standard
drug miltefosine as shown in Table 2. Among them,
compound 7 was found to have a very promising antil-
eishmanial activity with an IC50 value of 0.0128 μg/ml
which was 250 times superior than miltefosine (3.1911 μg/
ml). Compounds 8 and 11 were 30 times more active than
miltefosine. Compounds 6 and 12 were 10 times and twice
more active than miltefosine, respectively. Compounds 9
and 13 were as active as miltefosine.
All the synthesized compounds except compound 7
displayed weak antileishmanial activities as compared to
amphotericin B deoxycholate. Better antipromastigote
activity was observed for (E)-2-(4-chlorostyryl)-3-p-tolyl-
4(3H)-quinazolinone (7) with an IC50 value of 0.0128
μg/ml which is four times higher than the standard drug
amphotericin B deoxycholate with an IC50 value of
0.0128 μg/ml. (E)-2-(4-chlorostyryl)-3-p-tolyl-4(3H)-qui-
nazolinone (7) was found to be 4 times more active than
amphotericin B deoxycholate and 250 times more active
than miltefosine.
Oral acute toxicity study
Compound (E)-2-(4-chlorostyryl)-3-p-tolyl-4(3H)-quina-
zolinone (7) was observed to be devoid of any inherent
acute toxicities at a maximum dose of 300 mg/kg.
Experimental
Synthesis of target compounds
The synthesis of target compounds, 3-aryl-2-(substitu-
tedstyryl)-4(3H)-quinazolinones (6-9 and 11-13), was
achieved using cyclization, condensation, and hydrolysis
reactions. It involved the synthesis of acetanthranil (2-
methyl-3,1-benzoxazin-4-one (2)) and 3-aryl-2-methyl-4ed compounds
% yield Melting point (°C) Rf values [CHCl3/C6H6 (9:1)]
68.3 201 to 203 0.520
65.2 189 to 191 0.577
74.8 214 to 216 0.422
76.2 235 to 237 0.642
86.4 151 to 153 0.781
80.3 298 to 300 0.524
82.2 196 to 198 0.711
Table 2 Antipromastigote activity (IC50) of the
synthesized compounds









Amphotericin B 0.0460 46.00
IC50: effective concentration required to achieve 50% growth inhibition (in μg/ml).
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The details of each reactions and reaction conditions,
the summarized characteristic stretching and bending
IR vibration frequencies, the elemental microanalysis,
and the 1H NMR chemical shift data for each of the
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Scheme 1 Synthesis of 3-aryl-2-(substitutedstyryl)-4(3H)-quinazolinon
3-aryl-2-methyl-4(3H)-quinazolinones (3-5) as intermediates.General procedure for the synthesis of 2-methyl-3,1-benzox-
azin-4-one (2)
A solution of anthranillic acid (1) (10 g, 0.073 mol) in acetic
anhydride (25 ml) was heated under reflux for 1 h. The pre-
cipitate formed on cooling was filtered and the excess acetic
anhydride was washed with anhydrous petroleum ether,
where upon a solid mass is obtained. This solid mass (2),
without purification, was used for subsequent reaction [47].
General procedure for the synthesis of
3-aryl-2-methyl-4(3H)-quinazolinones (3-5)
A mixture of 2-methyl-3,1-benzoxazin-4-one (2) (3 g,
0.017 mol) and equimolar amounts of aromatic amines
(aniline, p-toluidine, and o-toluidine, respectively) was
heated under reflux at 190°C for 5 h. The dark sticky mass
formed were cooled and recrystallized from ethanol to
yield compounds 3-5, respectively [48].
General procedure for the synthesis of
3-aryl-2-(4-chlorostyryl)-4(3H)-quinazolinones (6 and 7)
To a solution of 3 or 4 (0.5 g each) in acetic anhydride
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es using acetanthranil (2-methyl-3,1-benzoxazin-4-one (2)) and
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chloride as a catalyst. The reaction mixture was heated
under reflux for 8 h, cooled, and poured into ice-cooled
water. The solid products formed (6 or 7) were filtered,
dried, and recrystallized from chloroform/ethanol (2:1) [49].
(E)-2-(4-chlorostyryl)-3-phenylquinazolin-4(3H)-one (6)
IR (Nujol) (cm−1): 1,682 (C =O), 1,597 (C =N), and 1,224
(C-Cl). 1H NMR (CDCl3) δ (ppm): 6.33 (d, 1H, J = 15.49
Hz, vinyl-C2 H), 7.23 (d, 2H, J = 8.53 Hz, 4-chlorophenyl
C3,5 H), 7.28 (d, 2H, J = 8.47 Hz, 4-chlorophenyl C2,6 H),
7.34 (d, 2H, J = 6.82 Hz, phenyl C2,6 H), 7.45 to 7.49 (m,
1H, quina-C6 H), 7.58 to 7.63 (m, 3H, phenyl C3,4,5 H),
7.75 to 7.79 (m, 2H, quina-C7,8 H), 7.91 (d, 1H, J = 15.47
Hz, vinyl-C1 H), 8.29 (d, 1H, J = 7.95 Hz, quina-C5). Anal.
calcd. for C22H17ClN2O: C, 73.23; H, 4.75; Cl, 9.83; N,
7.76. Found: C, 73.64; H, 4.92; Cl, 10.22; N, 7.54.
(E)-2-(4-chlorostyryl)-3-p-tolylquinazolin-4(3H)-one (7)
IR (Nujol) (cm−1): 1,682 (C =O), 1,597 (C =N), and 1,224
(C-Cl). 1H NMR (CDCl3) δ (ppm): 2.5 (s, 3H, p-tolyl
CH3), 6.42 (d, 1H, J = 15.70 Hz, vinyl-C2 H), 7.21 (d, 2H,
4-chlorophenyl C3,5 H), 7.26 to 7.32 (m, 4H, p-tolyl C2,3,5,6
H), 7.40 (d, 2H, 4-chlorophenyl C2,6 H), 7.47 to 7.51 (m,
1H, quina-C6 H), 7.79 to 7.83 (m, 2H, quina-C7,8 H), 7.93
(d, 1H, vinyl-C1 H), 8.32 (d, 1H, quina-C5 H). Anal. calcd.
for C23H19ClN2O: C, 73.69; H, 5.12; Cl, 9.46; N, 7.47.
Found: C, 73.98; H, 5.38; Cl, 9.35; N, 7.21.
General procedure for the synthesis of
3-aryl-2-(4-nitrostyryl)-4(3H)-quinazolinones (8 and 9)
To a solution of 4 or 5 (0.5 g each) in acetic anhydride
(10 ml), an equimolar amount of p-nitrobenzaldehyde was
added in the presence of 10 mg of anhydrous zinc chloride
as a catalyst. The reaction mixture was heated under
reflux for 8 h, cooled, and poured into ice-cooled water.
The solid products formed (8 or 9) were filtered, dried,
and recrystallized from chloroform/ethanol (2:1) [49].
(E)-2-(4-nitrostyryl)-3-p-tolylquinazolin-4(3H)-one (8)
IR (Nujol) (cm−1): 1,684 (C =O), 1,593 (C =N), 1,556
and 1,377 (NO2).
1H NMR (CDCl3) δ (ppm): 2.5 (s, 3H,
p-tolyl CH3), 6.56 (d, 1H, J = 15.52 Hz, vinyl-C2 H), 7.21
(d, 2H, J = 8.19 Hz, p-tolyl C3,5 H), 7.41 (d, 2H, J = 7.97
Hz, p-tolyl C2,6 H), 7.46 to 7.53 (m, 3H, 4-nitrophenyl
C2,6 and quina-C6), 7.77 to 7.81 (m, 2H, quina-C7,8), 8.00
(d, 1H, J = 15.52 Hz, vinyl-C1), 8.19 (d, 2H, J = 8.74 Hz,
4-nitrophenyl C3,5), 8.30 (d, 1H, J = 8.01 Hz, quina-C5).
Anal. calcd. for C23H18N3O3: C, 71.86; H, 4.72; N, 10.93.
Found: C, 72.12; H, 4.35; N, 11.10.
(E)-2-(4-nitrostyryl)-3-o-tolylquinazolin-4(3H)-one (9)
IR (Nujol) (cm−1): 1,682 (C =O), 1,593 (C =N), 1,556 and
1,377 (NO2).
1H NMR (CDCl3) δ (ppm): 2.17 (s, 3H, o-tolyl CH3), 6.47 (d, 1H, J = 15.66 Hz, vinyl-C2 H), 7.25
(d, 1H, J = 7.91 Hz, o-tolyl C3 H), 7.44 to 7.46 (m, 3H,
4-nitrophenyl C2,6 and o-tolyl C6 H), 7.47 to 7.58 (m,
3H, o-tolyl C4,5 and quina-C6 H), 7.82 to 7.89 (m, 2H,
quina-C7,8 H), 8.05 (d, 1H, J = 15.56 Hz, vinyl-C1 H),
8.19 (d, 2H, J = 8.73 Hz, 4-nitrophenyl C4,6 H), 8.36 (d, 1H,
J = 8.25 Hz, quina-C5 H). Anal. calcd. for C23H18N3O3: C,
71.86; H, 4.72; N, 10.93. Found: C, 71.68; H, 4.93; N, 11.24.
General procedure for the synthesis of 3-aryl-2-
(4-acetylatedstyryl)-4(3H)-quinazolinones (10)
To a solution of 3 (0.5 g) in acetic anhydride (10 ml), an
equimolar amount of p-hydroxybenzaldehyde was added.
Anhydrous zinc chloride (10 mg) is added as a catalyst. The
reaction mixture is heated under reflux for 8 h, cooled, and
poured into ice-cooled water. The solid product formed
(10) was filtered, dried, and recrystallized from ethanol [49].
General procedure for the synthesis of
3-aryl-2-(4-acetylatedstyryl)-4(3H)-quinazolinones (11)
To a solution of 5 (0.5 g) in acetic anhydride (10 ml), an
equimolar amount of vanillin was added. Anhydrous zinc
chloride (10 mg) is added as a catalyst. The reaction
mixture is heated under reflux for 8 h, cooled, and poured
into ice-cooled water. The solid product (11) was filtered,
dried, and recrystallized from ethanol [49].
4-{(1E)-2-[-3,4-dihydro-3-(2-methylphenyl)-4-oxoquinazoline-
2-yl)]vinyl}-2-methoxyphenyl acetate (11)
IR (Nujol) (cm−1): 1,761 (C = O), 1,682 (C = O), 1,634
(C = N), 1,260 and 1,149 (C-O-C). 1H NMR (CDCl3) δ
(ppm): 2.15 (s, 3H, phenylacetate CH3), 2.33 (s, 3H,
o-tolyl CH3), 3.80 (s, 3H, methoxy -O-CH3), 6.27 (d,
1H, J = 15.44 Hz, vinyl-C2 H), 6.88 to 6.93 (m, 2H, 2-
methoxyphenyl C3,5 H), 6.98 (d, 1H, J = 8.12 Hz, 2-
methoxyphenyl C6 H), 7.24 (d, 1H, J = 7.52 Hz, o-tolyl C3
H), 7.42 to 7.53 (m, 4H, o-tolyl C4,5,6 H and quina-C6 H),
7.82 to 7.83 (m, 2H, quina-C7,8 H), 7.96 (d, 1H, J = 15.48
Hz, vinyl-C1 H), 8.34 (d, 1H, J = 7.88 Hz, quina-C5 H).
Anal. calcd. for C26H24N2O4: C, 72.88; H, 5.65; N, 6.54.
Found: C, 73.11; H, 5.89; N, 6.42.
General procedure for the synthesis of 3-aryl-2-(4-deacetyla-
tedstyryl)-4(3H)-quinazolinones (12 and 13)
Subsequent treatment of 10 and 11 with 0.1 M alcoholic
KOH (5 ml) in the presence of ethanol followed by 0.1
M HCl (6 ml) gave the corresponding 4-hydroxyl con-
taining compounds 12 and 13 after recrystallization
from ethanol [49].
(E)-2-(4-hydroxystyryl)-3-phenylquinazolin-4(3H)-one (12)
IR (Nujol) (cm−1): 3,290 (OH), 1,652 (C =O), and 1,604
(C = N). 1H NMR (acetone-d6) δ (ppm): 6.24 (d, 1H, J =
15.39 Hz, vinyl-C2 H), 6.80 (d, 2H, J = 8.64 Hz, 4-
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hydroxyphenyl C2,6 H), 7.46 to 7.50 (m, 3H, phenyl C3,4,5
H), 7.60 to 7.66 (m, 3H, quina-C6, phenyl C2,6 H), 7.73
(d, 1H, J = 8.07 Hz, quina-C8 H), 7.81 to 7.85 (m, 1H,
quina-C7 H), 7.92 (d, 1H, J = 15.43 Hz, vinyl-C1 H), 8.02
(s, 1H, 4-hydroxyphenyl -OH), 8.17 (d, 1H, J = 9.18 Hz,
quina-C5 H). Anal. calcd. for C22H18N2O2: C, 7.17; H,
5.23; N, 8.18. Found: C, 76.86; H, 5.02; N, 8.38.
(E)-2-(4-hydroxy-3-methoxystyryl)-3-o-tolylquinazolin-4(3H)-
one (13)
IR (Nujol) (cm−1): 3,400 (OH), 1,683 (C = O), 1,634
(C = N), 1,211 and 1,148 (C-O-C). 1H NMR (CDCl3) δ
(ppm): 2.15 (s, 3H, o-tolyl CH3), 3.80 (s, 3H, 4-
hydroxy-2-methoxyphenyl -O-CH3), 6.10 (s, 1H, 4-
hydroxy-2-methoxyphenyl -OH), 6.27 (d, 1H, J = 15.44
Hz, vinyl-C2 H), 6.88 to 6.93 (m, 2H, 4-hydroxy-2-
methoxyphenyl C3,5 H), 6.98 (d, 1H, J = 8.12 Hz, 4-
hydroxy-2-methoxyphenyl C6 H), 7.24 (d, 1H, J = 7.52
Hz, o-tolyl C3 H), 7.42 to 7.53 (m, 4H, o-tolyl C4,5,6 H and
quina-C6 H), 7.82 (m, 2H, quina-C7,8 H), 7.96 (d, 1H,
J = 15.48 Hz, vinyl-C1 H), 8.34 (d, 1H, J = 7.884 Hz,
quina-C5 H). Anal. calcd. for C24H22N2O3: C, 74.59;
H, 5.74; N, 7.23. Found: C, 74.28; H, 5.96; N, 7.56.
Conclusions
Some 3-aryl-2-(substitutedstyryl)-4(3H)-quinazolinone de-
rivatives were synthesized and tested for their antileisha-
manial activities. Most of the synthesized compounds
displayed better antileishmanial activities as compared to
the standard drug miltefosine and lower antileishmanial
activity as compared to amphotericin B deoxycholate
except (E)-2-(4-chlorostyryl)-3-p-tolyl-4(3H)-quinazolinone
(7). Compound 7 showed pronounced antileishmanial
activities as compared to miltefosine and amphotericin B
deoxycholate. Thus, 2,3-disubstituted-4(3H)-quinazolinones
containing an aromatic substitution at 3-position and
substituted styryl moiety at 2-position represent a promis-
ing matrix for the development of antileishmanial agents.
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